Date of Presentation

5-2-2024 12:00 AM

College

Rowan-Virtua School of Osteopathic Medicine

Poster Abstract

Up to 70 million people worldwide suffer from vitiligo, an autoimmune disease characterized by the destruction of melanin. Current treatment options vary in efficacy. The disease manifests clinically as white circular macules of depigmentation seen primarily on the face and appendages.1 The pathophysiology of vitiligo is multifactorial and still being studied. One proposed mechanism behind the pathophysiology of vitiligo involves the upregulation of interferon gamma (IFN-γ) with downstream effects on JAK/STAT pathways resulting in CXCL10 transcription.1,2 Here we discuss Ruxolitinib, a topical JAK inhibitor, that recently passed its clinical trial phase, and Ritlecitinib, an oral JAK inhibitor which is currently undergoing clinical trials.3,4 These drugs are a reflection of the recent increase in targeted therapies for dermatologic diseases. The promising results of these drugs are widening the possible treatment options for patients that suffer from vitiligo.

Keywords

vitiligo, JAK inhibitors, ruxolitinib, ritlecitinib, Janus Kinase Inhibitors

Disciplines

Dermatology | Enzymes and Coenzymes | Integumentary System | Medicine and Health Sciences | Pathological Conditions, Signs and Symptoms | Skin and Connective Tissue Diseases | Therapeutics

Document Type

Poster

DOI

10.31986/issn.2689-0690_rdw.stratford_research_day.180_2024

Share

COinS
 
May 2nd, 12:00 AM

Janus Kinase (JAK) Inhibitors: A New Frontier in the Treatment of Vitiligo

Up to 70 million people worldwide suffer from vitiligo, an autoimmune disease characterized by the destruction of melanin. Current treatment options vary in efficacy. The disease manifests clinically as white circular macules of depigmentation seen primarily on the face and appendages.1 The pathophysiology of vitiligo is multifactorial and still being studied. One proposed mechanism behind the pathophysiology of vitiligo involves the upregulation of interferon gamma (IFN-γ) with downstream effects on JAK/STAT pathways resulting in CXCL10 transcription.1,2 Here we discuss Ruxolitinib, a topical JAK inhibitor, that recently passed its clinical trial phase, and Ritlecitinib, an oral JAK inhibitor which is currently undergoing clinical trials.3,4 These drugs are a reflection of the recent increase in targeted therapies for dermatologic diseases. The promising results of these drugs are widening the possible treatment options for patients that suffer from vitiligo.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.